Decoding YOD1: Insights into tumour regulation and translational opportunities
[Display omitted] YOD1 deubiquitinase is a 38 kDa protein that belongs to the ovarian tumour protease (OTU) family, and its dysregulation can precipitate cancer development. Still, an up-to-date review article that can summarize its detailed tumour-regulatory function and translational potentials in...
Saved in:
| Published in | Biochemical pharmacology Vol. 236; p. 116889 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Inc
01.06.2025
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | [Display omitted]
YOD1 deubiquitinase is a 38 kDa protein that belongs to the ovarian tumour protease (OTU) family, and its dysregulation can precipitate cancer development. Still, an up-to-date review article that can summarize its detailed tumour-regulatory function and translational potentials in different cancer types is lacking. To fill this literature gap, this review aims to discuss the tumour-modulatory role of YOD1 based on findings from different pre-clinical and clinical studies, followed by exploring the potential translational values of YOD1 as a tumour biomarker or therapeutic target. Overall, YOD1 could control the development of at least 15 tumour types by deubiquitinating or targeting different cellular proteins to modulate the activities of the cell cycle, p53, β-catenin, extracellular-regulated signal kinase (ERK), and YES-associated pathway (YAP) activities. Additionally, four long non-coding RNAs (lncRNAs), 12 microRNAs (miRNAs), and a few compounds can also directly or indirectly alter the expression and activity of YOD1, mediating tumourigenesis across different cancer types. Cellular expression data showed that YOD1 expression is dysregulated in eight cancer types, giving YOD1 the potential to be used as a diagnostic biomarker. Besides, YOD1 dysregulation can affect the clinical outcomes of various cancers. Hence, targeting YOD1 could potentially help slow tumourigenesis. The major drawback of considering YOD1 as a biomarker or therapeutic target is that its tumour-regulatory role is mainly based on the findings from single-center studies with relatively small sample sizes. Hence, future large-scale and in-depth clinical trials should be conducted to further verify the translational values of YOD1 as a biomarker or therapeutic target. |
|---|---|
| AbstractList | YOD1 deubiquitinase is a 38 kDa protein that belongs to the ovarian tumour protease (OTU) family, and its dysregulation can precipitate cancer development. Still, an up-to-date review article that can summarize its detailed tumour-regulatory function and translational potentials in different cancer types is lacking. To fill this literature gap, this review aims to discuss the tumour-modulatory role of YOD1 based on findings from different pre-clinical and clinical studies, followed by exploring the potential translational values of YOD1 as a tumour biomarker or therapeutic target. Overall, YOD1 could control the development of at least 15 tumour types by deubiquitinating or targeting different cellular proteins to modulate the activities of the cell cycle, p53, β-catenin, extracellular-regulated signal kinase (ERK), and YES-associated pathway (YAP) activities. Additionally, four long non-coding RNAs (lncRNAs), 12 microRNAs (miRNAs), and a few compounds can also directly or indirectly alter the expression and activity of YOD1, mediating tumourigenesis across different cancer types. Cellular expression data showed that YOD1 expression is dysregulated in eight cancer types, giving YOD1 the potential to be used as a diagnostic biomarker. Besides, YOD1 dysregulation can affect the clinical outcomes of various cancers. Hence, targeting YOD1 could potentially help slow tumourigenesis. The major drawback of considering YOD1 as a biomarker or therapeutic target is that its tumour-regulatory role is mainly based on the findings from single-center studies with relatively small sample sizes. Hence, future large-scale and in-depth clinical trials should be conducted to further verify the translational values of YOD1 as a biomarker or therapeutic target. YOD1 deubiquitinase is a 38 kDa protein that belongs to the ovarian tumour protease (OTU) family, and its dysregulation can precipitate cancer development. Still, an up-to-date review article that can summarize its detailed tumour-regulatory function and translational potentials in different cancer types is lacking. To fill this literature gap, this review aims to discuss the tumour-modulatory role of YOD1 based on findings from different pre-clinical and clinical studies, followed by exploring the potential translational values of YOD1 as a tumour biomarker or therapeutic target. Overall, YOD1 could control the development of at least 15 tumour types by deubiquitinating or targeting different cellular proteins to modulate the activities of the cell cycle, p53, β-catenin, extracellular-regulated signal kinase (ERK), and YES-associated pathway (YAP) activities. Additionally, four long non-coding RNAs (lncRNAs), 12 microRNAs (miRNAs), and a few compounds can also directly or indirectly alter the expression and activity of YOD1, mediating tumourigenesis across different cancer types. Cellular expression data showed that YOD1 expression is dysregulated in eight cancer types, giving YOD1 the potential to be used as a diagnostic biomarker. Besides, YOD1 dysregulation can affect the clinical outcomes of various cancers. Hence, targeting YOD1 could potentially help slow tumourigenesis. The major drawback of considering YOD1 as a biomarker or therapeutic target is that its tumour-regulatory role is mainly based on the findings from single-center studies with relatively small sample sizes. Hence, future large-scale and in-depth clinical trials should be conducted to further verify the translational values of YOD1 as a biomarker or therapeutic target.YOD1 deubiquitinase is a 38 kDa protein that belongs to the ovarian tumour protease (OTU) family, and its dysregulation can precipitate cancer development. Still, an up-to-date review article that can summarize its detailed tumour-regulatory function and translational potentials in different cancer types is lacking. To fill this literature gap, this review aims to discuss the tumour-modulatory role of YOD1 based on findings from different pre-clinical and clinical studies, followed by exploring the potential translational values of YOD1 as a tumour biomarker or therapeutic target. Overall, YOD1 could control the development of at least 15 tumour types by deubiquitinating or targeting different cellular proteins to modulate the activities of the cell cycle, p53, β-catenin, extracellular-regulated signal kinase (ERK), and YES-associated pathway (YAP) activities. Additionally, four long non-coding RNAs (lncRNAs), 12 microRNAs (miRNAs), and a few compounds can also directly or indirectly alter the expression and activity of YOD1, mediating tumourigenesis across different cancer types. Cellular expression data showed that YOD1 expression is dysregulated in eight cancer types, giving YOD1 the potential to be used as a diagnostic biomarker. Besides, YOD1 dysregulation can affect the clinical outcomes of various cancers. Hence, targeting YOD1 could potentially help slow tumourigenesis. The major drawback of considering YOD1 as a biomarker or therapeutic target is that its tumour-regulatory role is mainly based on the findings from single-center studies with relatively small sample sizes. Hence, future large-scale and in-depth clinical trials should be conducted to further verify the translational values of YOD1 as a biomarker or therapeutic target. [Display omitted] YOD1 deubiquitinase is a 38 kDa protein that belongs to the ovarian tumour protease (OTU) family, and its dysregulation can precipitate cancer development. Still, an up-to-date review article that can summarize its detailed tumour-regulatory function and translational potentials in different cancer types is lacking. To fill this literature gap, this review aims to discuss the tumour-modulatory role of YOD1 based on findings from different pre-clinical and clinical studies, followed by exploring the potential translational values of YOD1 as a tumour biomarker or therapeutic target. Overall, YOD1 could control the development of at least 15 tumour types by deubiquitinating or targeting different cellular proteins to modulate the activities of the cell cycle, p53, β-catenin, extracellular-regulated signal kinase (ERK), and YES-associated pathway (YAP) activities. Additionally, four long non-coding RNAs (lncRNAs), 12 microRNAs (miRNAs), and a few compounds can also directly or indirectly alter the expression and activity of YOD1, mediating tumourigenesis across different cancer types. Cellular expression data showed that YOD1 expression is dysregulated in eight cancer types, giving YOD1 the potential to be used as a diagnostic biomarker. Besides, YOD1 dysregulation can affect the clinical outcomes of various cancers. Hence, targeting YOD1 could potentially help slow tumourigenesis. The major drawback of considering YOD1 as a biomarker or therapeutic target is that its tumour-regulatory role is mainly based on the findings from single-center studies with relatively small sample sizes. Hence, future large-scale and in-depth clinical trials should be conducted to further verify the translational values of YOD1 as a biomarker or therapeutic target. |
| ArticleNumber | 116889 |
| Author | Zhi-Xiong, Chong |
| Author_xml | – sequence: 1 givenname: Chong surname: Zhi-Xiong fullname: Zhi-Xiong, Chong email: zxchong@nus.edu.sg, zhixiong17c@yahoo.com organization: Yong Loo Lin School of Medicine, National University of Singapore, Centre for Translational Medicine, 14 Medical Drive 117599, Singapore |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40132762$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kE1P4zAQhi3EClrYH8AF5cil3Zm4cRw4IVg-JLS9LIc9Wf5KcZXawXaQ-PebKsCR08wrPe9I88zJoQ_eEnKGsERA9mu7VLpfllBWS0TGeXNAZshruigbxg_JDADYuFflMZmntN1HzvCIHK8AaVmzckb-3FodjPOb4t_6Fi-LR5_c5iWnwvkcijzswhCLaDdDJ7MLvpDeFDlKn6YsuyL0fYh58C47m07Jj1Z2yf78mCfk-e7335uHxdP6_vHm-mmhKdR50SCFVW1qY9pGMaU041g1xgLWVcXoSlVgAFbYKmiAVqViXCJIbGtkrUFFT8jFdLeP4XWwKYudS9p2nfQ2DElQ5EgZqzgf0fMPdFA7a0Qf3U7Gd_HpYARwAnQMKUXbfiEIYu9ZbMXoWew9i8nz2LmaOnZ88s3ZKJJ21mtrXLQ6CxPcN-3_Y9qD-Q |
| Cites_doi | 10.3390/cancers13040888 10.1016/j.cellsig.2023.110725 10.1038/s41467-024-51284-y 10.1038/s41392-022-00975-3 10.1038/s41589-024-01777-0 10.1038/srep10775 10.3390/cancers14102486 10.3390/cells11182791 10.1016/j.molcel.2009.09.016 10.1186/s12967-024-05554-4 10.1186/s12967-024-05565-1 10.1186/s13045-024-01563-4 10.2217/nnm-2019-0218 10.1038/s41419-024-06731-5 10.1038/s41598-023-49565-5 10.1038/s41419-020-2254-1 10.1136/jitc-2023-008694 10.15252/embj.201695148 10.1101/gr.193342.115 10.3389/fimmu.2020.01030 10.1038/s41420-021-00556-3 10.1038/s12276-022-00890-1 10.62347/TQRB4608 10.3390/pharmaceutics15071796 10.4049/jimmunol.1800656 10.1038/s41419-023-06035-0 10.1038/s41420-023-01537-4 10.1002/1878-0261.13192 10.18632/oncotarget.19322 10.1038/s41420-021-00554-5 10.21037/tau-22-99 10.3389/fonc.2024.1362247 10.3390/cells8121535 10.1016/j.celrep.2023.112005 10.1038/s41392-022-01191-9 10.1038/s41467-022-35469-x 10.1016/j.ygeno.2023.110750 10.1073/pnas.1412944111 10.1038/s41408-024-01034-6 10.1016/j.ebiom.2024.105098 10.3892/mco.2024.2791 10.1016/j.fct.2024.114587 10.1016/j.bbrc.2019.07.058 10.18632/oncotarget.4702 10.1080/10428194.2023.2200516 10.1186/s12935-023-03078-3 10.3389/fgene.2021.633756 10.3390/cancers13194983 10.1098/rsob.200390 10.1016/0092-8674(93)80044-F 10.1016/j.bbrc.2021.01.045 10.3390/cancers13215432 10.1073/pnas.1620306114 10.3390/ph16010111 10.1016/j.jacbts.2024.06.001 10.1091/mbc.e13-06-0332 10.1186/s13045-024-01617-7 10.3390/cancers12030624 10.1073/pnas.052011299 10.3892/etm.2021.10567 10.3389/fnmol.2023.1175364 10.1073/pnas.2211937120 10.1016/j.urolonc.2018.08.001 10.1016/j.bbrc.2023.01.030 10.3389/fcell.2020.592164 10.1016/j.bbrc.2015.02.138 10.1016/j.jare.2020.06.026 10.3390/biom5021099 10.3389/fgene.2013.00224 10.1002/mog2.93 10.1186/s13046-023-02728-8 10.1038/s41467-024-45308-w 10.1186/s13046-020-01774-w 10.1038/s41392-024-01749-9 10.1186/s12935-022-02616-9 10.1186/s13058-020-01296-5 10.1038/s41401-024-01278-9 10.1155/2019/3136792 10.1002/jcp.28957 10.1083/jcb.202303015 10.1182/blood-2016-02-699439 10.1016/j.arr.2021.101367 10.1073/pnas.2221653120 10.1038/s41419-022-04766-0 10.1016/j.apsb.2021.10.020 10.1038/s12276-022-00792-2 10.1016/j.jgr.2023.04.004 10.1016/j.pharmthera.2014.11.002 10.3390/ijms221810177 10.1186/s13046-023-02781-3 10.1002/1878-0261.13077 10.1038/s41598-023-49241-8 10.1158/0008-5472.CAN-20-2801 10.1371/journal.pone.0110163 10.1016/j.bbadis.2024.167533 10.1038/s41419-020-2707-6 10.1093/nar/gkad1142 10.18632/oncotarget.2540 10.1016/j.chembiol.2024.05.001 10.1038/ncomms7156 10.1186/s12894-021-00810-x 10.1016/j.cell.2013.05.046 10.1016/j.isci.2024.109031 10.1016/j.nbd.2018.01.006 10.3389/fonc.2022.1062524 10.1002/jev2.12488 10.1186/s12943-024-02046-3 10.1021/acs.chemrev.6b00737 10.1016/j.prp.2023.154716 10.4172/2476-2261.1000129 10.1016/j.cell.2024.02.041 10.1016/j.biopha.2018.08.079 10.1038/s10038-020-00865-y 10.3892/mmr.2017.6975 10.3390/ijms21165667 10.1038/s41580-018-0086-y 10.1038/s41698-023-00407-7 10.1038/s41419-024-06939-5 10.1186/s12964-023-01396-7 |
| ContentType | Journal Article |
| Copyright | 2025 Elsevier Inc. Copyright © 2025 Elsevier Inc. All rights reserved. Copyright © 2025. Published by Elsevier Inc. |
| Copyright_xml | – notice: 2025 Elsevier Inc. – notice: Copyright © 2025 Elsevier Inc. All rights reserved. – notice: Copyright © 2025. Published by Elsevier Inc. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.bcp.2025.116889 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2968 |
| ExternalDocumentID | 40132762 10_1016_j_bcp_2025_116889 S0006295225001510 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- --K --M -~X .55 .GJ .HR .~1 0R~ 1B1 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYJJ ABFNM ABFRF ABJNI ABLJU ABMAC ABWVN ABXDB ABZDS ACDAQ ACGFO ACGFS ACIUM ACNCT ACRLP ACRPL ADBBV ADEZE ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AFFNX AFJKZ AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AI. AIEXJ AIKHN AITUG AKRWK ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LPU M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SES SEW SPCBC SPT SSH SSP SSZ T5K TEORI TWZ VH1 WH7 WUQ X7M ZGI ZXP ~G- AAYWO AAYXX ACVFH ADCNI AEUPX AFPUW AGRNS AIGII AIIUN AKBMS AKYEP CITATION CGR CUY CVF ECM EFKBS EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c307t-913047d7ddf9b6bbc68159de01755634b50d0041fb090352b68a10a1f716fd1b3 |
| IEDL.DBID | .~1 |
| ISSN | 0006-2952 1873-2968 |
| IngestDate | Wed Jul 02 05:14:07 EDT 2025 Mon Jul 21 05:57:46 EDT 2025 Tue Jul 01 05:02:31 EDT 2025 Sat Apr 26 15:42:07 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | IHC PTEN HR CDK PRDM1 RNF ncRNA TAZ Therapeutic target CTGF APML nTPM YY1 OTU PEDF TNM PSMD7 Deubiquitinase LATS ANKRD1 mTOR qPCR TIMP1 TNBC RFS AA AML GTEx RARα CAF YOD1 MAPK DUBRI EMT ERAD pLDDT TSS HNSCC HPA NF ADAM9 AMPK Tumour-regulation BPH HspBP1 STAMBP FC ERK RAI14 OTUB2 ceRNA Biomarker VCP HLF lncRNA MINDY2 BiP PTM XIAP YAP mRNA miRNA TGF-β SMAD GH HIF JUP KO OS CI TUG IGF AKT MARK PML ITCH MAVS REST USP DEX NEDD4 NTNBC TP XAF1 TRIM33 TS |
| Language | English |
| License | Copyright © 2025 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c307t-913047d7ddf9b6bbc68159de01755634b50d0041fb090352b68a10a1f716fd1b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 40132762 |
| PQID | 3181366588 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3181366588 pubmed_primary_40132762 crossref_primary_10_1016_j_bcp_2025_116889 elsevier_sciencedirect_doi_10_1016_j_bcp_2025_116889 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2025-06-01 |
| PublicationDateYYYYMMDD | 2025-06-01 |
| PublicationDate_xml | – month: 06 year: 2025 text: 2025-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Biochemical pharmacology |
| PublicationTitleAlternate | Biochem Pharmacol |
| PublicationYear | 2025 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Zhang, Bu, Shen, Shang, Chen, Zhang, Wang (b0385) 2021; 22 Guan, Shi, Zou, Sun, Zhan, Dong, Fan (b0380) 2021; 12 Ye, Chen, Qin, Tang, Li, Shi, Zhou (b0165) 2022; 11 Bao, Chen, Hou, Kang, Li, Xu (b0400) 2018; 107 Mazzeo, Ghosh, Di Cicco, Isma, Tavernari, Samarkina, Ostano, Youssef, Simon, Dotto (b0500) 2024; 15 Chen, Dang, Huang, Chen, Wu, Xu, Li, Yan (b0365) 2015; 6 Li, Zhang, You, Xu, Dai, Hua, Zhang, Yao, Zhou, Huang, Dai, Zhang, Baheti, Qian, Pu, Xu, Xia, Zhang, Tang, Wang (b0625) 2022; 13 Koussounadis, Langdon, Um, Harrison, Smith (b0200) 2015; 5 Gong, Liu, Sun, Xie, Yan, Cai (b0125) 2020; 15 Zhu, Al-Mathkour, Cao, Khalafi, Chen, Poveda, Peng, Lu, Soutto, Hu, McDonald, Zaika, El-Rifai (b0240) 2023; 42 Moya, Halder (b0460) 2019; 20 Lin, Zhu, Huang, Huang, Lin (b0130) 2022; 26 He, Wu, Sun, Chai (b0450) 2019; 517 Nguyen, Kugler, Loya, Cohen (b0285) 2017; 8 Kozalak, Bütün, Toyran, Koşar (b0580) 2023; 16 Liu, Banister, Weige, Altomare, Richardson, Contreras, Buckhaults (b0635) 2018; 115 Itoh, Takagane, Fukushi, Kuriyama, Umakoshi, Goto, Yanagihara, Yashiro, Tanaka (b0345) 2022; 16 Quinn, Vogel, Popp, Mertins, Lan, Messerschmidt, Landshammer, Lisek, Château-Joubert, Marangoni, Koren, Fuchs, Birchmeier (b0360) 2021; 81 Mevissen, Hospenthal, Geurink, Elliott, Akutsu, Arnaudo, Ekkebus, Kulathu, Wauer, El Oualid, Freund, Ovaa, Komander (b0180) 2013; 154 Wang, Zhang, Yan, Liu, Zhang (b0155) 2015; 459 Passaro, Al Bakir, Hamilton, Diehn, André, Roy-Chowdhuri, Mountzios, Wistuba, Swanton, Peters (b0540) 2024; 187 Correia de Sousa, Calo, Sobolewski, Gjorgjieva, Clément, Maeder, Dolicka, Fournier, Vinet, Montet, Dufour, Humar, Negro, Sempoux, Foti (b0505) 2021; 13 Okada, Koshizuka, Yamada, Moriya, Kikkawa, Kinoshita, Hanazawa, Seki (b0435) 2019; 8 Han, Jia, Zhang, Chen, Wang, Tong, He, Zhang, Zhu, Qin, Wang, Liu, Ma, Chen, Zha, Zhang (b0190) 2023; 42 Park, Do, Park, Choi, Baek (b0075) 2023; 645 . Rossio, Paulo, Liu, Gygi, King (b0030) 2024; 31 Chen, Li, Lu, Luo, Yang, Zhou, Tian, Tan, Liu (b0370) 2024; 14 Ye, Duan, Zhou, Wang, Lai, Yue, Cao, Wu, Wang, Jing (b0120) 2023; 108 Jia, He, Huang, Li, Dong, Liu (b0210) 2024; 9 Do, Baek (b0045) 2021; 69 An, Yu, Liu, Tang, Yang, Chen (b0040) 2024; 15 Piadel, Dalgleish, Smith (b0550) 2020; 1 Rhim, Baek, Seo, Kim (b0350) 2022; 11 Shen, Hu, Mao, Wu, Liu, Shen, Yu, Chen (b0420) 2020; 11 Aliabadi, Sohrabi, Mostafavi, Pazoki-Toroudi, Webster (b0600) 2021; 11 Keramati, Jafarian, Soltani, Javandoost, Mollaei, Fallah (b0390) 2021; 16 Zhang, Dong, Yan, Yu, Shan (b0415) 2020; 11 Qin, Zhao, Wang, Li, Li, Zhao, Wang, Zhao (b0470) 2024; 13 Merck, Ubiquitin Isopeptidase Inhibitor I, G5, (2024). Choi, Kim, Lee, Han, Bae, Han, Lee, Ham, Hur, Kim, Kim (b0495) 2024; 22 Wang, Xie, Liu, Li, Wang, Xie (b0445) 2021; 21 Wu, Duan, Han, Cao, Ye, Chen, Li, Wang, Liu, Fang, Yue, Wu, Wang, Jing (b0105) 2023; 14 Yan, Jin, Liu, Le, Gao, Cheng, Chen, Li (b0490) 2021; 543 Yang, Cui, Yang, Sun, Gao (b0485) 2017; 16 Grignani, Ferrucci, Testa, Talamo, Fagioli, Alcalay, Mencarelli, Grignani, Peschle, Nicoletti, Pelicci (b0335) 1993; 74 Cenik, Cenik, Byeon, Grubert, Candille, Spacek, Alsallakh, Tilgner, Araya, Tang, Ricci, Snyder (b0205) 2015; 25 Verheul, van Hijfte, Perenthaler, Barakat (b0410) 2020; 8 Wendrich, Gallant, Recknagel, Petroulia, Kazi, Hane, Führer, Bezstarosti, O’Dea, Demmers, Gersch (b0015) 2024 Kitareewan, Pitha-Rowe, Sekula, Lowrey, Nemeth, Golub, Freemantle, Dmitrovsky (b0325) 2002; 99 Sazonova, Kopeina, Imyanitov, Zhivotovsky (b0535) 2021; 7 Obidiro, Battogtokh, Akala (b0245) 2023; 15 Ernst, Mueller, Ploegh, Schlieker (b0175) 2009; 36 Grillone, Caridà, Luciano, Cordua, Di Martino, Tagliaferri, Tassone (b0655) 2024; 22 Huang, Wang, Lin, Li, Lu, Zhang, Shen, Tan, Qin, Chen, Chen, Pan, Wang, Zeng, Yang, Liu, Xing, Li, Zhang (b0270) 2023; 120 Sun, Fan, Deng, Wu (b0455) 2020; 235 Diener, Keller, Meese (b0650) 2024; 52 Yang, Yan, Zou, Xue, Lin, Huang, Li, Tang, Chen, Liu (b0440) 2022; 54 Dan, Shastri, Palagani, Buraschi, Neill, Savage, Kapoor, Deangelis, Addya, Camphausen, Iozzo, Simone (b0355) 2021; 13 Yin, Shen, Xu, Feng, Shi, Ju (b0115) 2023; 64 Seo, Choi, La, Kim, Kang, Kim, Choi (b0545) 2024; 20 Chen, Yang, Qin, Liu, Qiao, Wan, Zeng, Tang, Liu, Hou (b0280) 2021; 28 Park, Baek (b0290) 2023; 23 W. Alaswad RS, E. SM, S. HS, T. AD, Metformin targets glucose metabolism in triple negative breast cancer, J. Oncol. Transl. Res. 4 (2018) 129. doi: 10.4172/2476-2261.1000129. Ye, Chen, Chen, Xu, Jiang, Lin, Fang, Xu, Han, Han, Long, Wang, Zhou, Wu, Liang (b0050) 2024; 11 Korf, Wodrich, Haschke, Ocampo, Harder, Gieseke, Pollmann, Dierck, Prall, Staege, Ma, Horstmann, Evans, Sternsdorf (b0330) 2014; 111 Zhu, Chen, Shi, Zhu, Chen (b0140) 2020; 24 Ciszkowicz, Porzycki, Semik, Kaznowska, Tyrka (b0160) 2020; 21 Jiang, Bu, Zeng, Xia, Wu (b0375) 2019; 37 Chen, Yin, Jiang, He, Xie, Mao, Han, Liu, Lou, Wu, Habib, Yu, Liu, Pu (b0565) 2024; 12 Chen, Dragomir, Yang, Li, Horst, Calin (b0645) 2022; 7 Kim, Kim, Song, Kim, Cho, Moon, Ro, Seo, Ryu, Myung, Jho (b0215) 2017; 114 Costantini, Capone, Polo, Bagnara, Budillon (b0265) 2021; 22 Papadopoulos, Kirchner, Bug, Grum, Koerver, Schulze, Poehler, Dressler, Fengler, Arhzaouy, Lux, Ehrmann, Weihl, Meyer (b0065) 2017; 36 Ren, Ding, Zuo, Xu, Deng, Wei (b0195) 2020; 11 Shinden, Hirashima, Nohata, Toda, Okada, Asai, Tanaka, Hozaka, Ohtsuka, Kijima, Seki (b0145) 2021; 66 de la Cruz-Merino, Gion, Cruz-Jurado, Quiroga, Andrés, Moreno, Alonso-Romero, Ramos, Holgado, Cortés, López-Miranda, Henao-Carrasco, Palazón-Carrión, Rodríguez, Ceballos, Casas, Benito, Chiesa, Bezares, Caballero, Jiménez-Cortegana, Sánchez-Margalet, Rojo (b0555) 2021; 13 Tanji, Mori, Miki, Utsumi, Sasaki, Kakita, Takahashi, Wakabayashi (b0070) 2018; 112 Wang, Wang, Wang, Qi, Zhang, Wang, Zhang, Zhou, Gu, Yu, Zhou (b0295) 2023; 42 D’Arcy, Wang, Linder (b0595) 2015; 147 Lin, Chao, Lin, Hsu, Hsiao, Weng (b0615) 2024; 21 Tindall, Bailey-Lundberg, Cao, Ko (b0255) 2024; 14 Gao, Han, Jiang, Lu (b0340) 2023; 102 Wu, Qu, Bai, Zhu, Liu, Duan, Liu, Fu, Fan (b0610) 2024; 186 Tamai, Tatarano, Okamura, Fukumoto, Kawakami, Osako, Sakaguchi, Sugita, Yonemori, Yamada, Nakagawa, Enokida, Yoshino (b0430) 2022; 16 Wang, Wang, Wang, Tong, Tang, Wang, Zhang, Ou, Quan (b0150) 2021; 12 Farkas, Zsindely, Nagy, Kovács, Deák, Bodai (b0185) 2023; 13 Liu, Huang, Wang, Wen, Zheng, Wang, Fu, Tian, Li, Li, Wang (b0090) 2019; 202 Song, Gao, Bao, Chen, Huang, Liu, Dong, Wei (b0300) 2024; 17 Youyuan, Jingyong, He Ye, Zhiya, Chao, Rao Qishuo, Yiping, Ke (b0525) 2024; 16 Cappadocia, Lima (b0010) 2018; 118 Liu, Gong, Huang, Xu, Yang, Liu, Li (b0275) 2023; 248 Xiong, Li, Liu, Wang, Xiong, Chen, Chen, Yang, Tan, Luo, Peng, Xiao, Jiang (b0425) 2014; 9 Ji (b0510) 2015; 5 Lozada Ortiz, Betancor, Pérez Lázaro, Bolea, Badiola, Otero (b0035) 2023; 16 Villa, Dwivedi, Stahl, Hinkle, Rose, Kirkpatrick, Tomchik, Dixit, Wolf (b0020) 2024; 15 Liu, Chen, Li, Li, Zhu, Zhai, Lu, Fan, Liu, Chen, Jia, Dong, Liu (b0005) 2024; 23 Wang, Wang, Zhou, Mao, Zhan, Duan (b0640) 2024; 3 Liquori, Ibañez, Sargas, Sanz, Barragán, Cervera (b0320) 2020; 12 Yuan, Liao, Si, Huang, Li, Wang, Quan, Yu, Liao (b0515) 2025; 1871 Zhu, Hu, Chen, Zhou, Li, Wang, Zhao, Zhang, Zhao, Wang, Chen, Sun, Chen, Chen, Zhao, Mi, Shen, Wang, Chen, Chen, Li (b0315) 2016; 128 Wang, Bode, Zhang (b0235) 2023; 7 Han, Hu, Lau, Feng, Petrovic, Ji (b0520) 2013; 4 Pei, Peng, Zhuang, Wang, Lu, Guo, Zhao, Zhang, Xiao, Gao, Yu, He, Wu, Baek, Zhao, Xu, Chen (b0110) 2023; 9 Zhang, Zhao, Li, Li, Cheng, Zheng, Sun, Liu, Shao (b0095) 2022; 22 Lin, Jiang, Mei, Chen, Zheng, Han, Wu, Huang, Ye, Liang (b0080) 2024; 45 Bernardi, Williams, Inoue, Schultz, Tsai (b0170) 2013; 24 Cai, Wang, Chen, Zhang, Fu, Fan (b0135) 2024; 116 Pu, Xu, Nian, Fang, Yang, Huang, Li, Ge, Wang, Wei (b0100) 2021; 7 Yang, Li, Shang, Yao, Wu, Zhang, Zhang, Xu, Lu, Zhou, Huang, Huang, Cheng, Yang, Yu (b0220) 2020; 39 Mello, Flowers, Mazur, Lee, Müller, Denny, Ferreira, Hanson, Kim, Greenleaf, Wood, Attardi (b0260) 2023; 120 Park, Kim, Cho, Lee, Baek (b0085) 2020; 54 Cortes (b0620) 2024; 17 Chen, Zhang, Fu, Jiang, Wang (b0395) 2020; 24 Iyer, Elias, Stanchina, Watts (b0310) 2023; 12 Koltai, Reshkin, Carvalho, Di Molfetta, Greco, Alfarouk, Cardone (b0570) 2022; 14 Liu, Fan, Liu, Zhang, Tang, Liu, Zhang, Wu, Zhang, Qi, Shen (b0055) 2024; 15 Park, Yang, Seo, Nam, Nam (b0405) 2022; 54 Fu, Hu, Lan, Guan, Luo, Luo (b0465) 2022; 7 Matulka, Konopka, Mroczko, Pryczynicz, Kemona, Groblewska, Sieskiewicz, Olszewska (b0225) 2019; 2019 Huang, Hung, Tsai, Wu, Chou, Hsu, Chen, Wang, Yeh (b0575) 2024; 14 Xue, Chen, Wu, Wang, Zhou, Zhang, Lin, Aldape, Majumder, Lu, Huang (b0305) 2015; 6 Hoff, Banerjee, Khan, McCaughan, Wang, Wang, Roose, Anderson, Cowan, Rajkumar, Kaur (b0585) 2024; 14 Youn, Lee, Hariharasudhan, Kim, Kim, Lee, Lim, Yoon, Park, Chang, You (b0630) 2022; 13 Wu, Chen, Tian, Shao, Lin, Sun (b0025) 2024; 22 Xia, Ma, Shi, Liu, Zhang, Cao, Wang, Zheng, Ni, Xu, Zhu, Qiu, Ding, Huang, Liang, Chen, Xiang, Zhang, Qiu, Chen, Xie, Wang, Long, Li (b0230) 2024; 223 Shao, Chen, Wang, Du, Zhang, Cai, Bing, Cao, Xu, Yang, He, Ying (b0060) 2022; 12 Zhu, Xu, Wang, Zhang, Liu, Liang, Hua, Meng, Yu, Shi (b0560) 2024; 103 Yin, Duan, Bian, Yu (b0250) 2020; 22 Salah, Itzhaki, Aqeilan (b0475) 2014; 5 Ghomlaghi, Theocharous, Hoang, Shin, Kriegsheim, O’Neill, Zhang, Nguyen (b0480) 2024; 27 Li, Sun, Liu, Tang, Liu, Yin, Mi, Liu, Yu, Bi (b0605) 2023; 47 de la Cruz-Merino (10.1016/j.bcp.2025.116889_b0555) 2021; 13 Obidiro (10.1016/j.bcp.2025.116889_b0245) 2023; 15 Liquori (10.1016/j.bcp.2025.116889_b0320) 2020; 12 Liu (10.1016/j.bcp.2025.116889_b0275) 2023; 248 He (10.1016/j.bcp.2025.116889_b0450) 2019; 517 Passaro (10.1016/j.bcp.2025.116889_b0540) 2024; 187 Li (10.1016/j.bcp.2025.116889_b0625) 2022; 13 Shao (10.1016/j.bcp.2025.116889_b0060) 2022; 12 Xia (10.1016/j.bcp.2025.116889_b0230) 2024; 223 Park (10.1016/j.bcp.2025.116889_b0085) 2020; 54 Aliabadi (10.1016/j.bcp.2025.116889_b0600) 2021; 11 Farkas (10.1016/j.bcp.2025.116889_b0185) 2023; 13 Tanji (10.1016/j.bcp.2025.116889_b0070) 2018; 112 Jia (10.1016/j.bcp.2025.116889_b0210) 2024; 9 Chen (10.1016/j.bcp.2025.116889_b0565) 2024; 12 Koltai (10.1016/j.bcp.2025.116889_b0570) 2022; 14 Lozada Ortiz (10.1016/j.bcp.2025.116889_b0035) 2023; 16 Ye (10.1016/j.bcp.2025.116889_b0120) 2023; 108 Wang (10.1016/j.bcp.2025.116889_b0155) 2015; 459 Wu (10.1016/j.bcp.2025.116889_b0025) 2024; 22 Mazzeo (10.1016/j.bcp.2025.116889_b0500) 2024; 15 Grignani (10.1016/j.bcp.2025.116889_b0335) 1993; 74 Nguyen (10.1016/j.bcp.2025.116889_b0285) 2017; 8 Liu (10.1016/j.bcp.2025.116889_b0635) 2018; 115 Huang (10.1016/j.bcp.2025.116889_b0575) 2024; 14 Qin (10.1016/j.bcp.2025.116889_b0470) 2024; 13 D’Arcy (10.1016/j.bcp.2025.116889_b0595) 2015; 147 Matulka (10.1016/j.bcp.2025.116889_b0225) 2019; 2019 Iyer (10.1016/j.bcp.2025.116889_b0310) 2023; 12 Yin (10.1016/j.bcp.2025.116889_b0115) 2023; 64 Han (10.1016/j.bcp.2025.116889_b0190) 2023; 42 Lin (10.1016/j.bcp.2025.116889_b0615) 2024; 21 Yan (10.1016/j.bcp.2025.116889_b0490) 2021; 543 Koussounadis (10.1016/j.bcp.2025.116889_b0200) 2015; 5 Gao (10.1016/j.bcp.2025.116889_b0340) 2023; 102 Xiong (10.1016/j.bcp.2025.116889_b0425) 2014; 9 Liu (10.1016/j.bcp.2025.116889_b0005) 2024; 23 Itoh (10.1016/j.bcp.2025.116889_b0345) 2022; 16 Wendrich (10.1016/j.bcp.2025.116889_b0015) 2024 Chen (10.1016/j.bcp.2025.116889_b0370) 2024; 14 Dan (10.1016/j.bcp.2025.116889_b0355) 2021; 13 Huang (10.1016/j.bcp.2025.116889_b0270) 2023; 120 Park (10.1016/j.bcp.2025.116889_b0075) 2023; 645 Seo (10.1016/j.bcp.2025.116889_b0545) 2024; 20 Tamai (10.1016/j.bcp.2025.116889_b0430) 2022; 16 Song (10.1016/j.bcp.2025.116889_b0300) 2024; 17 Wang (10.1016/j.bcp.2025.116889_b0640) 2024; 3 Do (10.1016/j.bcp.2025.116889_b0045) 2021; 69 Sun (10.1016/j.bcp.2025.116889_b0455) 2020; 235 Liu (10.1016/j.bcp.2025.116889_b0090) 2019; 202 Cai (10.1016/j.bcp.2025.116889_b0135) 2024; 116 Guan (10.1016/j.bcp.2025.116889_b0380) 2021; 12 Han (10.1016/j.bcp.2025.116889_b0520) 2013; 4 Rhim (10.1016/j.bcp.2025.116889_b0350) 2022; 11 Sazonova (10.1016/j.bcp.2025.116889_b0535) 2021; 7 Ernst (10.1016/j.bcp.2025.116889_b0175) 2009; 36 Bernardi (10.1016/j.bcp.2025.116889_b0170) 2013; 24 Bao (10.1016/j.bcp.2025.116889_b0400) 2018; 107 Zhu (10.1016/j.bcp.2025.116889_b0140) 2020; 24 Yang (10.1016/j.bcp.2025.116889_b0440) 2022; 54 Ghomlaghi (10.1016/j.bcp.2025.116889_b0480) 2024; 27 Rossio (10.1016/j.bcp.2025.116889_b0030) 2024; 31 Ji (10.1016/j.bcp.2025.116889_b0510) 2015; 5 Wang (10.1016/j.bcp.2025.116889_b0235) 2023; 7 Chen (10.1016/j.bcp.2025.116889_b0645) 2022; 7 Pu (10.1016/j.bcp.2025.116889_b0100) 2021; 7 An (10.1016/j.bcp.2025.116889_b0040) 2024; 15 Lin (10.1016/j.bcp.2025.116889_b0130) 2022; 26 Papadopoulos (10.1016/j.bcp.2025.116889_b0065) 2017; 36 Mevissen (10.1016/j.bcp.2025.116889_b0180) 2013; 154 Zhang (10.1016/j.bcp.2025.116889_b0415) 2020; 11 Villa (10.1016/j.bcp.2025.116889_b0020) 2024; 15 Pei (10.1016/j.bcp.2025.116889_b0110) 2023; 9 Zhu (10.1016/j.bcp.2025.116889_b0240) 2023; 42 Lin (10.1016/j.bcp.2025.116889_b0080) 2024; 45 Ciszkowicz (10.1016/j.bcp.2025.116889_b0160) 2020; 21 Hoff (10.1016/j.bcp.2025.116889_b0585) 2024; 14 Kitareewan (10.1016/j.bcp.2025.116889_b0325) 2002; 99 Chen (10.1016/j.bcp.2025.116889_b0365) 2015; 6 Wang (10.1016/j.bcp.2025.116889_b0445) 2021; 21 Youyuan (10.1016/j.bcp.2025.116889_b0525) 2024; 16 10.1016/j.bcp.2025.116889_b0590 Park (10.1016/j.bcp.2025.116889_b0405) 2022; 54 Yang (10.1016/j.bcp.2025.116889_b0485) 2017; 16 Shen (10.1016/j.bcp.2025.116889_b0420) 2020; 11 Cortes (10.1016/j.bcp.2025.116889_b0620) 2024; 17 Salah (10.1016/j.bcp.2025.116889_b0475) 2014; 5 Li (10.1016/j.bcp.2025.116889_b0605) 2023; 47 Shinden (10.1016/j.bcp.2025.116889_b0145) 2021; 66 Costantini (10.1016/j.bcp.2025.116889_b0265) 2021; 22 Zhang (10.1016/j.bcp.2025.116889_b0385) 2021; 22 Liu (10.1016/j.bcp.2025.116889_b0055) 2024; 15 Yin (10.1016/j.bcp.2025.116889_b0250) 2020; 22 Ye (10.1016/j.bcp.2025.116889_b0165) 2022; 11 Mello (10.1016/j.bcp.2025.116889_b0260) 2023; 120 Kozalak (10.1016/j.bcp.2025.116889_b0580) 2023; 16 Piadel (10.1016/j.bcp.2025.116889_b0550) 2020; 1 Kim (10.1016/j.bcp.2025.116889_b0215) 2017; 114 Yuan (10.1016/j.bcp.2025.116889_b0515) 2025; 1871 Cenik (10.1016/j.bcp.2025.116889_b0205) 2015; 25 Okada (10.1016/j.bcp.2025.116889_b0435) 2019; 8 Quinn (10.1016/j.bcp.2025.116889_b0360) 2021; 81 Zhang (10.1016/j.bcp.2025.116889_b0095) 2022; 22 Chen (10.1016/j.bcp.2025.116889_b0280) 2021; 28 Tindall (10.1016/j.bcp.2025.116889_b0255) 2024; 14 Jiang (10.1016/j.bcp.2025.116889_b0375) 2019; 37 Chen (10.1016/j.bcp.2025.116889_b0395) 2020; 24 Verheul (10.1016/j.bcp.2025.116889_b0410) 2020; 8 Zhu (10.1016/j.bcp.2025.116889_b0560) 2024; 103 Ren (10.1016/j.bcp.2025.116889_b0195) 2020; 11 Keramati (10.1016/j.bcp.2025.116889_b0390) 2021; 16 Korf (10.1016/j.bcp.2025.116889_b0330) 2014; 111 Wang (10.1016/j.bcp.2025.116889_b0150) 2021; 12 Wu (10.1016/j.bcp.2025.116889_b0105) 2023; 14 10.1016/j.bcp.2025.116889_b0530 Youn (10.1016/j.bcp.2025.116889_b0630) 2022; 13 Ye (10.1016/j.bcp.2025.116889_b0050) 2024; 11 Park (10.1016/j.bcp.2025.116889_b0290) 2023; 23 Yang (10.1016/j.bcp.2025.116889_b0220) 2020; 39 Gong (10.1016/j.bcp.2025.116889_b0125) 2020; 15 Xue (10.1016/j.bcp.2025.116889_b0305) 2015; 6 Moya (10.1016/j.bcp.2025.116889_b0460) 2019; 20 Grillone (10.1016/j.bcp.2025.116889_b0655) 2024; 22 Zhu (10.1016/j.bcp.2025.116889_b0315) 2016; 128 Choi (10.1016/j.bcp.2025.116889_b0495) 2024; 22 Wang (10.1016/j.bcp.2025.116889_b0295) 2023; 42 Fu (10.1016/j.bcp.2025.116889_b0465) 2022; 7 Correia de Sousa (10.1016/j.bcp.2025.116889_b0505) 2021; 13 Diener (10.1016/j.bcp.2025.116889_b0650) 2024; 52 Cappadocia (10.1016/j.bcp.2025.116889_b0010) 2018; 118 Wu (10.1016/j.bcp.2025.116889_b0610) 2024; 186 |
| References_xml | – volume: 26 start-page: 8903 year: 2022 end-page: 8913 ident: b0130 article-title: Paclitaxel-resistant related lncRNA DBH-AS1 promotes the proliferation and invasion of esophageal cancer publication-title: Eur. Rev. Med. Pharmacol. Sci. – volume: 9 year: 2014 ident: b0425 article-title: Integrated microRNA and mRNA transcriptome sequencing reveals the potential roles of miRNAs in stage I endometrioid endometrial carcinoma publication-title: PLoS One – volume: 28 start-page: 195 year: 2021 end-page: 208 ident: b0280 article-title: Effects of differential distributed-JUP on the malignancy of gastric cancer publication-title: J. Adv. Res. – volume: 517 start-page: 581 year: 2019 end-page: 587 ident: b0450 article-title: MiR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m6A-caused stabilization of SEC62 publication-title: Biochem. Biophys. Res. Commun. – volume: 4 start-page: 224 year: 2013 ident: b0520 article-title: Altered methylation and expression of ER-associated degradation factors in long-term alcohol and constitutive ER stress-induced murine hepatic tumors publication-title: Front. Genet. – volume: 21 start-page: 93 year: 2024 ident: b0615 article-title: Efficacy and safety of second-generation FLT3 inhibitors in acute myeloid leukemia: a systematic review and meta-analysis of randomized controlled trials publication-title: Mol. Clin. Oncol. – volume: 22 start-page: 985 year: 2024 ident: b0025 article-title: Ubiquitination regulates autophagy in cancer: simple modifications, promising targets publication-title: J. Transl. Med. – volume: 543 start-page: 56 year: 2021 end-page: 64 ident: b0490 article-title: Dexmedetomidine inhibits cell malignancy in osteosarcoma cells via miR-520a-3p-YOD1 interactome publication-title: Biochem. Biophys. Res. Commun. – volume: 39 start-page: 251 year: 2020 ident: b0220 article-title: WNT4 secreted by tumor tissues promotes tumor progression in colorectal cancer by activation of the Wnt/β-catenin signalling pathway publication-title: J. Exp. Clin. Cancer Res. – volume: 14 start-page: 3523 year: 2024 end-page: 3532 ident: b0575 article-title: Efficacy of first-line combination therapies versus gemcitabine monotherapy for advanced pancreatic cancer: a systematic review and network meta-analysis publication-title: Am. J. Cancer Res. – volume: 16 start-page: 3565 year: 2017 end-page: 3572 ident: b0485 article-title: MicroRNA-302a suppresses cell proliferation, migration and invasion in osteosarcoma by targeting ADAM9 publication-title: Mol. Med. Rep. – volume: 23 start-page: 209 year: 2023 ident: b0290 article-title: Synergistic effect of YOD1 and USP21 on the Hippo signaling pathway publication-title: Cancer Cell Int. – volume: 17 start-page: 46 year: 2024 ident: b0300 article-title: Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy publication-title: J. Hematol. Oncol. – volume: 1871 year: 2025 ident: b0515 article-title: Trim21 modulates endoplasmic reticulum-associated degradation and sensitizes cancer cells to ER stress-induced apoptosis by inhibiting VCP/Npl4/UFD1 assembly publication-title: Biochim. Biophys. Acta Mol. basis Dis. – volume: 7 start-page: 182 year: 2021 ident: b0100 article-title: M2 macrophage-derived extracellular vesicles facilitate CD8+T cell exhaustion in hepatocellular carcinoma via the miR-21-5p/YOD1/YAP/β-catenin pathway publication-title: Cell Death Discov. – volume: 187 start-page: 1617 year: 2024 end-page: 1635 ident: b0540 article-title: Cancer biomarkers: emerging trends and clinical implications for personalized treatment publication-title: Cell – volume: 52 start-page: 1544 year: 2024 end-page: 1557 ident: b0650 article-title: The miRNA–target interactions: an underestimated intricacy publication-title: Nucleic Acids Res. – volume: 9 start-page: 44 year: 2024 ident: b0210 article-title: Protein translation: biological processes and therapeutic strategies for human diseases publication-title: Signal Transduct. Target. Ther. – volume: 2019 year: 2019 ident: b0225 article-title: Expression and concentration of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinases 1 in laryngeal squamous cell carcinoma publication-title: Dis. Markers – volume: 107 start-page: 824 year: 2018 end-page: 833 ident: b0400 article-title: LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway publication-title: Biomed. Pharmacother. – volume: 102 year: 2023 ident: b0340 article-title: Transformation from acute promyelocytic leukemia in pregnancy to acute myeloid leukemia with MLL-AF9 fusion gene: a case report and literature review publication-title: Medicine (United States) – volume: 14 start-page: 124 year: 2024 ident: b0370 article-title: miR-373 promotes invasion and metastasis of colorectal cancer cells via activating ERK/MAPK pathway publication-title: Sci. Rep. – volume: 1 start-page: 107 year: 2020 end-page: 120 ident: b0550 article-title: Gemcitabine in the era of cancer immunotherapy publication-title: J. Clin. Haematol. – volume: 16 year: 2023 ident: b0035 article-title: Endoplasmic reticulum stress and ubiquitin-proteasome system impairment in natural scrapie publication-title: Front. Mol. Neurosci. – volume: 154 start-page: 169 year: 2013 end-page: 184 ident: b0180 article-title: OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis publication-title: Cell – volume: 23 start-page: 148 year: 2024 ident: b0005 article-title: Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches publication-title: Mol. Cancer – volume: 31 start-page: 1349 year: 2024 end-page: 1362.e5 ident: b0030 article-title: Specificity profiling of deubiquitylases against endogenously generated ubiquitin-protein conjugates publication-title: Cell Chem. Biol. – volume: 21 start-page: 40 year: 2021 ident: b0445 article-title: MicroRNA-4429 suppresses proliferation of prostate cancer cells by targeting distal-less homeobox 1 and inactivating the Wnt/β-catenin pathway publication-title: BMC Urol. – volume: 21 start-page: 5667 year: 2020 ident: b0160 article-title: Mir-93/mir-375: diagnostic potential, aggressiveness correlation and common target genes in prostate cancer publication-title: Int. J. Mol. Sci. – volume: 11 start-page: 2791 year: 2022 ident: b0350 article-title: From molecular mechanisms to therapeutics: understanding microRNA-21 in cancer publication-title: Cells – volume: 13 start-page: 309 year: 2022 ident: b0630 article-title: HspBP1 is a dual function regulatory protein that controls both DNA repair and apoptosis in breast cancer cells publication-title: Cell Death Dis. – volume: 13 start-page: 5432 year: 2021 ident: b0555 article-title: Pembrolizumab plus gemcitabine in the subset of triple-negative advanced breast cancer patients in the geicam/2015-04 (PANGEA-Breast) study publication-title: Cancers (Basel) – volume: 459 start-page: 515 year: 2015 end-page: 520 ident: b0155 article-title: MicroRNA-373 functions as an oncogene and targets YOD1 gene in cervical cancer publication-title: Biochem. Biophys. Res. Commun. – volume: 36 start-page: 28 year: 2009 end-page: 38 ident: b0175 article-title: The Otubain YOD1 is a deubiquitinating enzyme that associates with p97 to facilitate protein dislocation from the ER publication-title: Mol. Cell – volume: 6 start-page: 6156 year: 2015 ident: b0305 article-title: Tumour suppressor TRIM33 targets nuclear β-catenin degradation publication-title: Nat. Commun. – volume: 13 start-page: 21951 year: 2023 ident: b0185 article-title: The ubiquitin thioesterase YOD1 ameliorates mutant Huntingtin induced pathology in Drosophila publication-title: Sci. Rep. – volume: 5 start-page: 10886 year: 2014 end-page: 10900 ident: b0475 article-title: The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway publication-title: Oncotarget – volume: 24 start-page: 8722 year: 2020 end-page: 8730 ident: b0140 article-title: MiR-4429 suppresses the malignant development of ovarian cancer by targeting YOD1 publication-title: Eur. Rev. Med. Pharmacol. Sci. – volume: 120 year: 2023 ident: b0260 article-title: Multifaceted role for p53 in pancreatic cancer suppression publication-title: PNAS – volume: 27 year: 2024 ident: b0480 article-title: Integrative modeling and analysis of signaling crosstalk reveal molecular switches coordinating Yes-associated protein transcriptional activities publication-title: IScience – volume: 12 year: 2023 ident: b0310 article-title: The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions publication-title: Front. Oncol. – volume: 186 year: 2024 ident: b0610 article-title: Ginsenoside Rk1 induces autophagy-dependent apoptosis in hepatocellular carcinoma by AMPK/mTOR signaling pathway publication-title: Food Chem. Toxicol. – volume: 103 year: 2024 ident: b0560 article-title: Intratumoral CD38 + CD19 + B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma publication-title: EBioMedicine – volume: 15 start-page: 1796 year: 2023 ident: b0245 article-title: Triple negative breast cancer treatment options and limitations: future outlook publication-title: Pharmaceutics – volume: 108 year: 2023 ident: b0120 article-title: Hypoxic tumor-derived exosomal miR-21 induces cancer-associated fibroblast activation to promote head and neck squamous cell carcinoma metastasis publication-title: Cell. Signal. – volume: 7 start-page: 155 year: 2021 ident: b0535 article-title: Platinum drugs and taxanes: can we overcome resistance? publication-title: Cell Death Discov. – volume: 22 start-page: 203 year: 2022 ident: b0095 article-title: YOD1 serves as a potential prognostic biomarker for pancreatic cancer publication-title: Cancer Cell Int. – volume: 14 year: 2024 ident: b0255 article-title: The TGF-β superfamily as potential therapeutic targets in pancreatic cancer publication-title: Front. Oncol. – volume: 16 start-page: 166 year: 2022 end-page: 187 ident: b0345 article-title: Cancer-associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and T-cell suppression publication-title: Mol. Oncol. – volume: 12 year: 2021 ident: b0380 article-title: EZH2-mediated microRNA-375 upregulation promotes progression of breast cancer via the inhibition of FOXO1 and the p53 signaling pathway publication-title: Front. Genet. – volume: 15 start-page: 1038 year: 2024 ident: b0500 article-title: ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation publication-title: Nat. Commun. – volume: 112 start-page: 14 year: 2018 end-page: 23 ident: b0070 article-title: YOD1 attenuates neurogenic proteotoxicity through its deubiquitinating activity publication-title: Neurobiol. Dis. – volume: 645 start-page: 124 year: 2023 end-page: 131 ident: b0075 article-title: Deubiquitinating enzyme YOD1 deubiquitinates and destabilizes α-synuclein publication-title: Biochem. Biophys. Res. Commun. – volume: 11 start-page: 65 year: 2020 ident: b0420 article-title: The long noncoding RNA TUG1 is required for TGF-β/TWIST1/EMT-mediated metastasis in colorectal cancer cells publication-title: Cell Death Dis. – volume: 7 start-page: 376 year: 2022 ident: b0465 article-title: The Hippo signalling pathway and its implications in human health and diseases publication-title: Signal Transduct. Target. Ther. – volume: 5 start-page: 10775 year: 2015 ident: b0200 article-title: Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system publication-title: Sci. Rep. – volume: 7 start-page: 58 year: 2023 ident: b0235 article-title: Targeting CDK1 in cancer: mechanisms and implications publication-title: NPJ Precis. Oncol. – volume: 22 start-page: 61 year: 2020 ident: b0250 article-title: Triple-negative breast cancer molecular subtyping and treatment progress publication-title: Breast Cancer Res. – volume: 14 start-page: 517 year: 2023 ident: b0105 article-title: Deubiquitinase YOD1 suppresses tumor progression by stabilizing E3 ligase TRIM33 in head and neck squamous cell carcinoma publication-title: Cell Death Dis. – volume: 118 start-page: 889 year: 2018 end-page: 918 ident: b0010 article-title: Ubiquitin-like protein conjugation: Structures, chemistry, and mechanism publication-title: Chem. Rev. – volume: 64 start-page: 1161 year: 2023 end-page: 1174 ident: b0115 article-title: YY1-induced LncRNA-TUG1 elevates YOD1 to promote cell proliferation and inhibit bortezomib sensitivity in multiple myeloma publication-title: Leuk. Lymphoma – volume: 25 start-page: 1610 year: 2015 end-page: 1621 ident: b0205 article-title: Integrative analysis of RNA, translation, and protein levels reveals distinct regulatory variation across humans publication-title: Genome Res. – volume: 12 start-page: 1856 year: 2022 end-page: 1870 ident: b0060 article-title: Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells publication-title: Acta Pharm. Sin. B – volume: 24 start-page: 3545 year: 2013 end-page: 3556 ident: b0170 article-title: A deubiquitinase negatively regulates retro-translocation of nonubiquitinated substrates publication-title: Mol. Biol. Cell – volume: 6 start-page: 32701 year: 2015 end-page: 32712 ident: b0365 article-title: MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1α-TWIST signaling axis in breast cancer publication-title: Oncotarget – volume: 54 start-page: 812 year: 2022 end-page: 824 ident: b0405 article-title: hnRNPC induces isoform shifts in miR-21-5p leading to cancer development publication-title: Exp. Mol. Med. – volume: 22 start-page: 731 year: 2024 ident: b0655 article-title: A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer publication-title: J. Transl. Med. – volume: 11 start-page: 643 year: 2022 end-page: 658 ident: b0165 article-title: Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer publication-title: Transl. Androl. Urol. – volume: 20 start-page: 211 year: 2019 end-page: 226 ident: b0460 article-title: Hippo–YAP/TAZ signalling in organ regeneration and regenerative medicine publication-title: Nat. Rev. Mol. Cell Biol. – volume: 13 start-page: 888 year: 2021 ident: b0355 article-title: MiR-21 plays a dual role in tumor formation and cytotoxic response in breast tumors publication-title: Cancers (Basel) – volume: 45 start-page: 1618 year: 2024 end-page: 1631 ident: b0080 article-title: Endothelial deubiquinatase YOD1 mediates Ang II-induced vascular endothelial-mesenchymal transition and remodeling by regulating β-catenin publication-title: Acta Pharmacol. Sin. – volume: 120 year: 2023 ident: b0270 article-title: Nuclear VCP drives colorectal cancer progression by promoting fatty acid oxidation publication-title: PNAS – volume: 147 start-page: 32 year: 2015 end-page: 54 ident: b0595 article-title: Deubiquitinase inhibition as a cancer therapeutic strategy publication-title: Pharmacol. Ther. – volume: 99 start-page: 3806 year: 2002 end-page: 3811 ident: b0325 article-title: UBE1L is a retinoid target that triggers PMLRAR degradation and apoptosis in acute promyelocytic leukemia publication-title: Proc. Natl. Acad. Sci. USA – volume: 22 start-page: 8 year: 2024 ident: b0495 article-title: Characterization of gastric cancer-stimulated signaling pathways and function of CTGF in cancer-associated fibroblasts publication-title: Cell Commun. Signal. – volume: 248 year: 2023 ident: b0275 article-title: RNF114 facilitates the proliferation, stemness, and metastasis of colorectal cancer publication-title: Pathol. Res. Pract. – volume: 54 start-page: 1 year: 2020 end-page: 14 ident: b0085 article-title: YOD1 deubiquitinates Nedd4 involved in the Hippo signaling pathway publication-title: Cell. Physiol. Biochem. – volume: 9 start-page: 249 year: 2023 ident: b0110 article-title: miR-221/222 induce instability of p53 by downregulating deubiquitinase YOD1 in acute myeloid leukemia publication-title: Cell Death Discov. – reference: Merck, Ubiquitin Isopeptidase Inhibitor I, G5, (2024). – volume: 13 year: 2024 ident: b0470 article-title: Extracellular vesicles miR-31-5p promotes pancreatic cancer chemoresistance via regulating LATS2-Hippo pathway and promoting SPARC secretion from pancreatic stellate cells publication-title: J. Extracell Vesicles – volume: 66 start-page: 519 year: 2021 end-page: 534 ident: b0145 article-title: Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes publication-title: J. Hum. Genet. – year: 2024 ident: b0015 article-title: Discovery and mechanism of K63-linkage-directed deubiquitinase activity in USP53 publication-title: Nat. Chem. Biol. – volume: 128 start-page: 1525 year: 2016 end-page: 1528 ident: b0315 article-title: The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia publication-title: Blood – volume: 8 start-page: 1535 year: 2019 ident: b0435 article-title: Regulation of oncogenic targets by miR-99a-3p (passenger strand of miR-99a-duplex) in head and neck squamous cell carcinoma publication-title: Cells – volume: 14 start-page: 2486 year: 2022 ident: b0570 article-title: Resistance to gemcitabine in pancreatic ductal adenocarcinoma: a physiopathologic and pharmacologic review publication-title: Cancers (Basel) – volume: 7 start-page: 121 year: 2022 ident: b0645 article-title: Targeting non-coding RNAs to overcome cancer therapy resistance publication-title: Signal Transduct. Target. Ther. – volume: 16 start-page: 11553 year: 2024 end-page: 11567 ident: b0525 article-title: The deubiquitinating enzymes related signature predicts the prognosis and immunotherapy response in breast cancer publication-title: Aging (Albany NY) – volume: 116 year: 2024 ident: b0135 article-title: LncRNA FIRRE regulated endometrial cancer radiotherapy sensitivity via the miR-199b-5p/SIRT1/BECN1 axis-mediated autophagy publication-title: Genomics – volume: 114 start-page: 4691 year: 2017 end-page: 4696 ident: b0215 article-title: Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability publication-title: PNAS – volume: 13 start-page: 7677 year: 2022 ident: b0625 article-title: PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells publication-title: Nat. Commun. – volume: 8 year: 2020 ident: b0410 article-title: The Why of YY1: mechanisms of transcriptional regulation by Yin Yang 1 publication-title: Front. Cell Dev. Biol. – volume: 74 start-page: 423 year: 1993 end-page: 431 ident: b0335 article-title: The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells publication-title: Cell – volume: 12 year: 2021 ident: b0150 article-title: Long non-coding RNA FIRRE acts as a miR-520a-3p sponge to promote gallbladder cancer progression via mediating YOD1 expression publication-title: Front. Genet. – volume: 36 start-page: 135 year: 2017 end-page: 150 ident: b0065 article-title: VCP/p97 cooperates with YOD 1, UBXD 1 and PLAA to drive clearance of ruptured lysosomes by autophagy publication-title: EMBO J. – volume: 37 start-page: 150 year: 2019 end-page: 157 ident: b0375 article-title: MicroRNA-93 promotes bladder cancer proliferation and invasion by targeting PEDF publication-title: Urol. Oncol. – volume: 5 start-page: 1099 year: 2015 end-page: 1121 ident: b0510 article-title: Advances and new concepts in alcohol-induced organelle stress, unfolded protein responses and organ damage publication-title: Biomolecules – volume: 3 start-page: e93 year: 2024 ident: b0640 article-title: miRNA interplay: mechanisms and therapeutic interventions in cancer publication-title: MedComm - Oncology – volume: 11 year: 2021 ident: b0600 article-title: Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy publication-title: Open Biol. – volume: 15 start-page: 360 year: 2024 ident: b0055 article-title: YOD1 protects against MRSA sepsis-induced DIC through Lys33-linked deubiquitination of NLRP3 publication-title: Cell Death Dis. – volume: 8 start-page: 64095 year: 2017 end-page: 64105 ident: b0285 article-title: USP21 regulates Hippo pathway activity by mediating MARK protein turnover publication-title: Oncotarget – volume: 47 start-page: 645 year: 2023 end-page: 653 ident: b0605 article-title: Ginsenoside Rk1 inhibits HeLa cell proliferation through an endoplasmic reticulum signaling pathway publication-title: J. Ginseng Res. – volume: 16 year: 2021 ident: b0390 article-title: Circulating miRNAs can serve as potential diagnostic biomarkers in chronic myelogenous leukemia patients publication-title: Leuk. Res. Rep. – volume: 22 start-page: 10177 year: 2021 ident: b0265 article-title: Valosin-containing protein (VCP)/p97: a prognostic biomarker and therapeutic target in cancer publication-title: Int. J. Mol. Sci. – reference: W. Alaswad RS, E. SM, S. HS, T. AD, Metformin targets glucose metabolism in triple negative breast cancer, J. Oncol. Transl. Res. 4 (2018) 129. doi: 10.4172/2476-2261.1000129. – volume: 16 start-page: 1329 year: 2022 end-page: 1346 ident: b0430 article-title: microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1 publication-title: Mol. Oncol. – volume: 14 start-page: 52 year: 2024 ident: b0585 article-title: Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis publication-title: Blood Cancer J. – volume: 42 year: 2023 ident: b0240 article-title: CDK1 bridges NF-κB and β-catenin signaling in response to H. pylori infection in gastric tumorigenesis publication-title: Cell Rep. – volume: 42 start-page: 228 year: 2023 ident: b0190 article-title: Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis publication-title: J. Exp. Clin. Cancer Res. – volume: 15 start-page: 711 year: 2020 end-page: 723 ident: b0125 article-title: Polyethylenimine-dextran-coated magnetic nanoparticles loaded with miR-302b suppress osteosarcoma in vitro and in vivo publication-title: Nanomedicine – volume: 15 start-page: 556 year: 2024 ident: b0040 article-title: Oxidative cell death in cancer: mechanisms and therapeutic opportunities publication-title: Cell Death Dis. – volume: 115 start-page: E5066 year: 2018 end-page: E5075 ident: b0635 article-title: PRDM1 silences stem cell-related genes and inhibits proliferation of human colon tumor organoids publication-title: PNAS – volume: 111 start-page: 12133 year: 2014 end-page: 12138 ident: b0330 article-title: The PML domain of PML-RARα blocks senescence to promote leukemia publication-title: PNAS – volume: 11 start-page: 542 year: 2020 ident: b0415 article-title: CircAGFG1 drives metastasis and stemness in colorectal cancer by modulating YY1/CTNNB1 publication-title: Cell Death Dis. – volume: 54 start-page: 2047 year: 2022 end-page: 2059 ident: b0440 article-title: The deubiquitinating enzyme STAMBP is a newly discovered driver of triple-negative breast cancer progression that maintains RAI14 protein stability publication-title: Exp. Mol. Med. – volume: 17 start-page: 111 year: 2024 ident: b0620 article-title: Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML publication-title: J. Hematol. Oncol. – volume: 24 start-page: 7698 year: 2020 end-page: 7708 ident: b0395 article-title: LncRNA DBH-AS1 facilitates the tumorigenesis of melanoma by targeting miR-223-3p via IGF-1R/AKT signaling publication-title: Eur. Rev. Med. Pharmacol. Sci. – reference: . – volume: 22 start-page: 1133 year: 2021 ident: b0385 article-title: MicroRNA–221 regulates cell activity and apoptosis in acute lymphoblastic leukemia via regulating PTEN publication-title: Exp. Ther. Med. – volume: 12 year: 2024 ident: b0565 article-title: Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer publication-title: J. Immunother. Cancer – volume: 11 start-page: 1030 year: 2020 ident: b0195 article-title: Regulation of MAVS expression and signaling function in the antiviral innate immune response publication-title: Front. Immunol. – volume: 223 year: 2024 ident: b0230 article-title: XAF1 promotes colorectal cancer metastasis via VCP–RNF114–JUP axis publication-title: J. Cell Biol. – volume: 20 year: 2024 ident: b0545 article-title: Multi-biomarker profiling for precision diagnosis of lung cancer publication-title: Small – volume: 15 start-page: 6873 year: 2024 ident: b0020 article-title: OTUD6 deubiquitination of RPS7/eS7 on the free 40 S ribosome regulates global protein translation and stress publication-title: Nat. Commun. – volume: 12 start-page: 624 year: 2020 ident: b0320 article-title: Acute promyelocytic leukemia: a constellation of molecular events around a single PML-RARA fusion gene publication-title: Cancers (Basel) – volume: 69 year: 2021 ident: b0045 article-title: Cellular functions regulated by deubiquitinating enzymes in neurodegenerative diseases publication-title: Ageing Res. Rev. – volume: 202 start-page: 2957 year: 2019 end-page: 2970 ident: b0090 article-title: The otubain YOD1 suppresses aggregation and activation of the signaling adaptor MAVS through Lys63-linked deubiquitination publication-title: J. Immunol. – volume: 11 start-page: 1287 year: 2024 end-page: 1304 ident: b0050 article-title: Deubiquitinase USP25 alleviates obesity-induced cardiac remodeling and dysfunction by downregulating TAK1 and reducing TAK1-mediated inflammation publication-title: JACC Basic Transl. Sci. – volume: 16 start-page: 111 year: 2023 ident: b0580 article-title: Review on Bortezomib resistance in multiple myeloma and potential role of emerging technologies publication-title: Pharmaceuticals – volume: 81 start-page: 2116 year: 2021 end-page: 2127 ident: b0360 article-title: YAP and β-Catenin cooperate to drive oncogenesis in basal breast cancer publication-title: Cancer Res. – volume: 13 year: 2021 ident: b0505 article-title: Mir-21 suppression promotes mouse hepatocarcinogenesis publication-title: Cancers (Basel) – volume: 42 start-page: 161 year: 2023 ident: b0295 article-title: Chronic stress accelerates glioblastoma progression via DRD2/ERK/β-catenin axis and Dopamine/ERK/TH positive feedback loop publication-title: J. Exp. Clin. Cancer Res. – volume: 235 start-page: 185 year: 2020 end-page: 193 ident: b0455 article-title: miR-4429 sensitized cervical cancer cells to irradiation by targeting RAD51 publication-title: J. Cell. Physiol. – volume: 54 start-page: 1 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0085 article-title: YOD1 deubiquitinates Nedd4 involved in the Hippo signaling pathway publication-title: Cell. Physiol. Biochem. – volume: 13 start-page: 888 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0355 article-title: MiR-21 plays a dual role in tumor formation and cytotoxic response in breast tumors publication-title: Cancers (Basel) doi: 10.3390/cancers13040888 – volume: 108 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0120 article-title: Hypoxic tumor-derived exosomal miR-21 induces cancer-associated fibroblast activation to promote head and neck squamous cell carcinoma metastasis publication-title: Cell. Signal. doi: 10.1016/j.cellsig.2023.110725 – volume: 15 start-page: 6873 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0020 article-title: OTUD6 deubiquitination of RPS7/eS7 on the free 40 S ribosome regulates global protein translation and stress publication-title: Nat. Commun. doi: 10.1038/s41467-024-51284-y – volume: 7 start-page: 121 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0645 article-title: Targeting non-coding RNAs to overcome cancer therapy resistance publication-title: Signal Transduct. Target. Ther. doi: 10.1038/s41392-022-00975-3 – year: 2024 ident: 10.1016/j.bcp.2025.116889_b0015 article-title: Discovery and mechanism of K63-linkage-directed deubiquitinase activity in USP53 publication-title: Nat. Chem. Biol. doi: 10.1038/s41589-024-01777-0 – volume: 12 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0150 article-title: Long non-coding RNA FIRRE acts as a miR-520a-3p sponge to promote gallbladder cancer progression via mediating YOD1 expression publication-title: Front. Genet. – volume: 5 start-page: 10775 year: 2015 ident: 10.1016/j.bcp.2025.116889_b0200 article-title: Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system publication-title: Sci. Rep. doi: 10.1038/srep10775 – volume: 102 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0340 article-title: Transformation from acute promyelocytic leukemia in pregnancy to acute myeloid leukemia with MLL-AF9 fusion gene: a case report and literature review publication-title: Medicine (United States) – volume: 14 start-page: 2486 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0570 article-title: Resistance to gemcitabine in pancreatic ductal adenocarcinoma: a physiopathologic and pharmacologic review publication-title: Cancers (Basel) doi: 10.3390/cancers14102486 – volume: 11 start-page: 2791 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0350 article-title: From molecular mechanisms to therapeutics: understanding microRNA-21 in cancer publication-title: Cells doi: 10.3390/cells11182791 – volume: 36 start-page: 28 year: 2009 ident: 10.1016/j.bcp.2025.116889_b0175 article-title: The Otubain YOD1 is a deubiquitinating enzyme that associates with p97 to facilitate protein dislocation from the ER publication-title: Mol. Cell doi: 10.1016/j.molcel.2009.09.016 – volume: 22 start-page: 731 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0655 article-title: A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer publication-title: J. Transl. Med. doi: 10.1186/s12967-024-05554-4 – volume: 22 start-page: 985 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0025 article-title: Ubiquitination regulates autophagy in cancer: simple modifications, promising targets publication-title: J. Transl. Med. doi: 10.1186/s12967-024-05565-1 – volume: 17 start-page: 46 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0300 article-title: Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-024-01563-4 – volume: 15 start-page: 711 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0125 article-title: Polyethylenimine-dextran-coated magnetic nanoparticles loaded with miR-302b suppress osteosarcoma in vitro and in vivo publication-title: Nanomedicine doi: 10.2217/nnm-2019-0218 – volume: 26 start-page: 8903 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0130 article-title: Paclitaxel-resistant related lncRNA DBH-AS1 promotes the proliferation and invasion of esophageal cancer publication-title: Eur. Rev. Med. Pharmacol. Sci. – volume: 15 start-page: 360 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0055 article-title: YOD1 protects against MRSA sepsis-induced DIC through Lys33-linked deubiquitination of NLRP3 publication-title: Cell Death Dis. doi: 10.1038/s41419-024-06731-5 – volume: 14 start-page: 124 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0370 article-title: miR-373 promotes invasion and metastasis of colorectal cancer cells via activating ERK/MAPK pathway publication-title: Sci. Rep. doi: 10.1038/s41598-023-49565-5 – volume: 11 start-page: 65 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0420 article-title: The long noncoding RNA TUG1 is required for TGF-β/TWIST1/EMT-mediated metastasis in colorectal cancer cells publication-title: Cell Death Dis. doi: 10.1038/s41419-020-2254-1 – volume: 12 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0565 article-title: Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2023-008694 – volume: 36 start-page: 135 year: 2017 ident: 10.1016/j.bcp.2025.116889_b0065 article-title: VCP/p97 cooperates with YOD 1, UBXD 1 and PLAA to drive clearance of ruptured lysosomes by autophagy publication-title: EMBO J. doi: 10.15252/embj.201695148 – volume: 1 start-page: 107 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0550 article-title: Gemcitabine in the era of cancer immunotherapy publication-title: J. Clin. Haematol. – volume: 25 start-page: 1610 year: 2015 ident: 10.1016/j.bcp.2025.116889_b0205 article-title: Integrative analysis of RNA, translation, and protein levels reveals distinct regulatory variation across humans publication-title: Genome Res. doi: 10.1101/gr.193342.115 – volume: 11 start-page: 1030 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0195 article-title: Regulation of MAVS expression and signaling function in the antiviral innate immune response publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.01030 – volume: 7 start-page: 182 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0100 article-title: M2 macrophage-derived extracellular vesicles facilitate CD8+T cell exhaustion in hepatocellular carcinoma via the miR-21-5p/YOD1/YAP/β-catenin pathway publication-title: Cell Death Discov. doi: 10.1038/s41420-021-00556-3 – volume: 54 start-page: 2047 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0440 article-title: The deubiquitinating enzyme STAMBP is a newly discovered driver of triple-negative breast cancer progression that maintains RAI14 protein stability publication-title: Exp. Mol. Med. doi: 10.1038/s12276-022-00890-1 – volume: 14 start-page: 3523 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0575 article-title: Efficacy of first-line combination therapies versus gemcitabine monotherapy for advanced pancreatic cancer: a systematic review and network meta-analysis publication-title: Am. J. Cancer Res. doi: 10.62347/TQRB4608 – volume: 15 start-page: 1796 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0245 article-title: Triple negative breast cancer treatment options and limitations: future outlook publication-title: Pharmaceutics doi: 10.3390/pharmaceutics15071796 – volume: 202 start-page: 2957 year: 2019 ident: 10.1016/j.bcp.2025.116889_b0090 article-title: The otubain YOD1 suppresses aggregation and activation of the signaling adaptor MAVS through Lys63-linked deubiquitination publication-title: J. Immunol. doi: 10.4049/jimmunol.1800656 – volume: 14 start-page: 517 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0105 article-title: Deubiquitinase YOD1 suppresses tumor progression by stabilizing E3 ligase TRIM33 in head and neck squamous cell carcinoma publication-title: Cell Death Dis. doi: 10.1038/s41419-023-06035-0 – volume: 16 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0390 article-title: Circulating miRNAs can serve as potential diagnostic biomarkers in chronic myelogenous leukemia patients publication-title: Leuk. Res. Rep. – volume: 9 start-page: 249 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0110 article-title: miR-221/222 induce instability of p53 by downregulating deubiquitinase YOD1 in acute myeloid leukemia publication-title: Cell Death Discov. doi: 10.1038/s41420-023-01537-4 – volume: 16 start-page: 1329 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0430 article-title: microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1 publication-title: Mol. Oncol. doi: 10.1002/1878-0261.13192 – volume: 8 start-page: 64095 year: 2017 ident: 10.1016/j.bcp.2025.116889_b0285 article-title: USP21 regulates Hippo pathway activity by mediating MARK protein turnover publication-title: Oncotarget doi: 10.18632/oncotarget.19322 – volume: 7 start-page: 155 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0535 article-title: Platinum drugs and taxanes: can we overcome resistance? publication-title: Cell Death Discov. doi: 10.1038/s41420-021-00554-5 – volume: 11 start-page: 643 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0165 article-title: Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer publication-title: Transl. Androl. Urol. doi: 10.21037/tau-22-99 – volume: 14 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0255 article-title: The TGF-β superfamily as potential therapeutic targets in pancreatic cancer publication-title: Front. Oncol. doi: 10.3389/fonc.2024.1362247 – volume: 8 start-page: 1535 year: 2019 ident: 10.1016/j.bcp.2025.116889_b0435 article-title: Regulation of oncogenic targets by miR-99a-3p (passenger strand of miR-99a-duplex) in head and neck squamous cell carcinoma publication-title: Cells doi: 10.3390/cells8121535 – volume: 42 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0240 article-title: CDK1 bridges NF-κB and β-catenin signaling in response to H. pylori infection in gastric tumorigenesis publication-title: Cell Rep. doi: 10.1016/j.celrep.2023.112005 – volume: 7 start-page: 376 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0465 article-title: The Hippo signalling pathway and its implications in human health and diseases publication-title: Signal Transduct. Target. Ther. doi: 10.1038/s41392-022-01191-9 – volume: 13 start-page: 7677 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0625 article-title: PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells publication-title: Nat. Commun. doi: 10.1038/s41467-022-35469-x – volume: 116 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0135 article-title: LncRNA FIRRE regulated endometrial cancer radiotherapy sensitivity via the miR-199b-5p/SIRT1/BECN1 axis-mediated autophagy publication-title: Genomics doi: 10.1016/j.ygeno.2023.110750 – volume: 111 start-page: 12133 year: 2014 ident: 10.1016/j.bcp.2025.116889_b0330 article-title: The PML domain of PML-RARα blocks senescence to promote leukemia publication-title: PNAS doi: 10.1073/pnas.1412944111 – volume: 14 start-page: 52 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0585 article-title: Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis publication-title: Blood Cancer J. doi: 10.1038/s41408-024-01034-6 – volume: 103 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0560 article-title: Intratumoral CD38 + CD19 + B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma publication-title: EBioMedicine doi: 10.1016/j.ebiom.2024.105098 – volume: 21 start-page: 93 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0615 article-title: Efficacy and safety of second-generation FLT3 inhibitors in acute myeloid leukemia: a systematic review and meta-analysis of randomized controlled trials publication-title: Mol. Clin. Oncol. doi: 10.3892/mco.2024.2791 – volume: 186 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0610 article-title: Ginsenoside Rk1 induces autophagy-dependent apoptosis in hepatocellular carcinoma by AMPK/mTOR signaling pathway publication-title: Food Chem. Toxicol. doi: 10.1016/j.fct.2024.114587 – volume: 517 start-page: 581 year: 2019 ident: 10.1016/j.bcp.2025.116889_b0450 article-title: MiR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m6A-caused stabilization of SEC62 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2019.07.058 – volume: 6 start-page: 32701 year: 2015 ident: 10.1016/j.bcp.2025.116889_b0365 article-title: MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1α-TWIST signaling axis in breast cancer publication-title: Oncotarget doi: 10.18632/oncotarget.4702 – volume: 64 start-page: 1161 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0115 article-title: YY1-induced LncRNA-TUG1 elevates YOD1 to promote cell proliferation and inhibit bortezomib sensitivity in multiple myeloma publication-title: Leuk. Lymphoma doi: 10.1080/10428194.2023.2200516 – volume: 23 start-page: 209 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0290 article-title: Synergistic effect of YOD1 and USP21 on the Hippo signaling pathway publication-title: Cancer Cell Int. doi: 10.1186/s12935-023-03078-3 – volume: 16 start-page: 11553 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0525 article-title: The deubiquitinating enzymes related signature predicts the prognosis and immunotherapy response in breast cancer publication-title: Aging (Albany NY) – volume: 20 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0545 article-title: Multi-biomarker profiling for precision diagnosis of lung cancer publication-title: Small – volume: 12 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0380 article-title: EZH2-mediated microRNA-375 upregulation promotes progression of breast cancer via the inhibition of FOXO1 and the p53 signaling pathway publication-title: Front. Genet. doi: 10.3389/fgene.2021.633756 – volume: 13 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0505 article-title: Mir-21 suppression promotes mouse hepatocarcinogenesis publication-title: Cancers (Basel) doi: 10.3390/cancers13194983 – volume: 11 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0600 article-title: Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy publication-title: Open Biol. doi: 10.1098/rsob.200390 – volume: 74 start-page: 423 year: 1993 ident: 10.1016/j.bcp.2025.116889_b0335 article-title: The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells publication-title: Cell doi: 10.1016/0092-8674(93)80044-F – volume: 543 start-page: 56 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0490 article-title: Dexmedetomidine inhibits cell malignancy in osteosarcoma cells via miR-520a-3p-YOD1 interactome publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2021.01.045 – volume: 13 start-page: 5432 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0555 article-title: Pembrolizumab plus gemcitabine in the subset of triple-negative advanced breast cancer patients in the geicam/2015-04 (PANGEA-Breast) study publication-title: Cancers (Basel) doi: 10.3390/cancers13215432 – volume: 114 start-page: 4691 year: 2017 ident: 10.1016/j.bcp.2025.116889_b0215 article-title: Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability publication-title: PNAS doi: 10.1073/pnas.1620306114 – volume: 16 start-page: 111 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0580 article-title: Review on Bortezomib resistance in multiple myeloma and potential role of emerging technologies publication-title: Pharmaceuticals doi: 10.3390/ph16010111 – volume: 11 start-page: 1287 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0050 article-title: Deubiquitinase USP25 alleviates obesity-induced cardiac remodeling and dysfunction by downregulating TAK1 and reducing TAK1-mediated inflammation publication-title: JACC Basic Transl. Sci. doi: 10.1016/j.jacbts.2024.06.001 – volume: 24 start-page: 3545 year: 2013 ident: 10.1016/j.bcp.2025.116889_b0170 article-title: A deubiquitinase negatively regulates retro-translocation of nonubiquitinated substrates publication-title: Mol. Biol. Cell doi: 10.1091/mbc.e13-06-0332 – volume: 17 start-page: 111 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0620 article-title: Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-024-01617-7 – volume: 12 start-page: 624 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0320 article-title: Acute promyelocytic leukemia: a constellation of molecular events around a single PML-RARA fusion gene publication-title: Cancers (Basel) doi: 10.3390/cancers12030624 – volume: 99 start-page: 3806 year: 2002 ident: 10.1016/j.bcp.2025.116889_b0325 article-title: UBE1L is a retinoid target that triggers PMLRAR degradation and apoptosis in acute promyelocytic leukemia publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.052011299 – volume: 22 start-page: 1133 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0385 article-title: MicroRNA–221 regulates cell activity and apoptosis in acute lymphoblastic leukemia via regulating PTEN publication-title: Exp. Ther. Med. doi: 10.3892/etm.2021.10567 – volume: 16 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0035 article-title: Endoplasmic reticulum stress and ubiquitin-proteasome system impairment in natural scrapie publication-title: Front. Mol. Neurosci. doi: 10.3389/fnmol.2023.1175364 – volume: 120 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0260 article-title: Multifaceted role for p53 in pancreatic cancer suppression publication-title: PNAS doi: 10.1073/pnas.2211937120 – volume: 37 start-page: 150 year: 2019 ident: 10.1016/j.bcp.2025.116889_b0375 article-title: MicroRNA-93 promotes bladder cancer proliferation and invasion by targeting PEDF publication-title: Urol. Oncol. doi: 10.1016/j.urolonc.2018.08.001 – volume: 645 start-page: 124 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0075 article-title: Deubiquitinating enzyme YOD1 deubiquitinates and destabilizes α-synuclein publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2023.01.030 – volume: 8 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0410 article-title: The Why of YY1: mechanisms of transcriptional regulation by Yin Yang 1 publication-title: Front. Cell Dev. Biol. doi: 10.3389/fcell.2020.592164 – volume: 459 start-page: 515 year: 2015 ident: 10.1016/j.bcp.2025.116889_b0155 article-title: MicroRNA-373 functions as an oncogene and targets YOD1 gene in cervical cancer publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2015.02.138 – volume: 28 start-page: 195 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0280 article-title: Effects of differential distributed-JUP on the malignancy of gastric cancer publication-title: J. Adv. Res. doi: 10.1016/j.jare.2020.06.026 – volume: 5 start-page: 1099 year: 2015 ident: 10.1016/j.bcp.2025.116889_b0510 article-title: Advances and new concepts in alcohol-induced organelle stress, unfolded protein responses and organ damage publication-title: Biomolecules doi: 10.3390/biom5021099 – volume: 4 start-page: 224 year: 2013 ident: 10.1016/j.bcp.2025.116889_b0520 article-title: Altered methylation and expression of ER-associated degradation factors in long-term alcohol and constitutive ER stress-induced murine hepatic tumors publication-title: Front. Genet. doi: 10.3389/fgene.2013.00224 – volume: 3 start-page: e93 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0640 article-title: miRNA interplay: mechanisms and therapeutic interventions in cancer publication-title: MedComm - Oncology doi: 10.1002/mog2.93 – volume: 115 start-page: E5066 year: 2018 ident: 10.1016/j.bcp.2025.116889_b0635 article-title: PRDM1 silences stem cell-related genes and inhibits proliferation of human colon tumor organoids publication-title: PNAS – volume: 42 start-page: 161 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0295 article-title: Chronic stress accelerates glioblastoma progression via DRD2/ERK/β-catenin axis and Dopamine/ERK/TH positive feedback loop publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-023-02728-8 – volume: 15 start-page: 1038 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0500 article-title: ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation publication-title: Nat. Commun. doi: 10.1038/s41467-024-45308-w – volume: 39 start-page: 251 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0220 article-title: WNT4 secreted by tumor tissues promotes tumor progression in colorectal cancer by activation of the Wnt/β-catenin signalling pathway publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-020-01774-w – volume: 9 start-page: 44 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0210 article-title: Protein translation: biological processes and therapeutic strategies for human diseases publication-title: Signal Transduct. Target. Ther. doi: 10.1038/s41392-024-01749-9 – volume: 22 start-page: 203 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0095 article-title: YOD1 serves as a potential prognostic biomarker for pancreatic cancer publication-title: Cancer Cell Int. doi: 10.1186/s12935-022-02616-9 – volume: 22 start-page: 61 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0250 article-title: Triple-negative breast cancer molecular subtyping and treatment progress publication-title: Breast Cancer Res. doi: 10.1186/s13058-020-01296-5 – volume: 45 start-page: 1618 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0080 article-title: Endothelial deubiquinatase YOD1 mediates Ang II-induced vascular endothelial-mesenchymal transition and remodeling by regulating β-catenin publication-title: Acta Pharmacol. Sin. doi: 10.1038/s41401-024-01278-9 – volume: 2019 year: 2019 ident: 10.1016/j.bcp.2025.116889_b0225 article-title: Expression and concentration of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinases 1 in laryngeal squamous cell carcinoma publication-title: Dis. Markers doi: 10.1155/2019/3136792 – volume: 235 start-page: 185 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0455 article-title: miR-4429 sensitized cervical cancer cells to irradiation by targeting RAD51 publication-title: J. Cell. Physiol. doi: 10.1002/jcp.28957 – volume: 223 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0230 article-title: XAF1 promotes colorectal cancer metastasis via VCP–RNF114–JUP axis publication-title: J. Cell Biol. doi: 10.1083/jcb.202303015 – volume: 128 start-page: 1525 year: 2016 ident: 10.1016/j.bcp.2025.116889_b0315 article-title: The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia publication-title: Blood doi: 10.1182/blood-2016-02-699439 – volume: 69 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0045 article-title: Cellular functions regulated by deubiquitinating enzymes in neurodegenerative diseases publication-title: Ageing Res. Rev. doi: 10.1016/j.arr.2021.101367 – volume: 120 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0270 article-title: Nuclear VCP drives colorectal cancer progression by promoting fatty acid oxidation publication-title: PNAS doi: 10.1073/pnas.2221653120 – volume: 13 start-page: 309 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0630 article-title: HspBP1 is a dual function regulatory protein that controls both DNA repair and apoptosis in breast cancer cells publication-title: Cell Death Dis. doi: 10.1038/s41419-022-04766-0 – volume: 12 start-page: 1856 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0060 article-title: Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells publication-title: Acta Pharm. Sin. B doi: 10.1016/j.apsb.2021.10.020 – volume: 54 start-page: 812 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0405 article-title: hnRNPC induces isoform shifts in miR-21-5p leading to cancer development publication-title: Exp. Mol. Med. doi: 10.1038/s12276-022-00792-2 – volume: 47 start-page: 645 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0605 article-title: Ginsenoside Rk1 inhibits HeLa cell proliferation through an endoplasmic reticulum signaling pathway publication-title: J. Ginseng Res. doi: 10.1016/j.jgr.2023.04.004 – volume: 147 start-page: 32 year: 2015 ident: 10.1016/j.bcp.2025.116889_b0595 article-title: Deubiquitinase inhibition as a cancer therapeutic strategy publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2014.11.002 – volume: 22 start-page: 10177 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0265 article-title: Valosin-containing protein (VCP)/p97: a prognostic biomarker and therapeutic target in cancer publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms221810177 – volume: 42 start-page: 228 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0190 article-title: Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-023-02781-3 – volume: 16 start-page: 166 year: 2022 ident: 10.1016/j.bcp.2025.116889_b0345 article-title: Cancer-associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and T-cell suppression publication-title: Mol. Oncol. doi: 10.1002/1878-0261.13077 – volume: 13 start-page: 21951 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0185 article-title: The ubiquitin thioesterase YOD1 ameliorates mutant Huntingtin induced pathology in Drosophila publication-title: Sci. Rep. doi: 10.1038/s41598-023-49241-8 – volume: 81 start-page: 2116 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0360 article-title: YAP and β-Catenin cooperate to drive oncogenesis in basal breast cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-20-2801 – volume: 9 year: 2014 ident: 10.1016/j.bcp.2025.116889_b0425 article-title: Integrated microRNA and mRNA transcriptome sequencing reveals the potential roles of miRNAs in stage I endometrioid endometrial carcinoma publication-title: PLoS One doi: 10.1371/journal.pone.0110163 – volume: 1871 year: 2025 ident: 10.1016/j.bcp.2025.116889_b0515 article-title: Trim21 modulates endoplasmic reticulum-associated degradation and sensitizes cancer cells to ER stress-induced apoptosis by inhibiting VCP/Npl4/UFD1 assembly publication-title: Biochim. Biophys. Acta Mol. basis Dis. doi: 10.1016/j.bbadis.2024.167533 – volume: 11 start-page: 542 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0415 article-title: CircAGFG1 drives metastasis and stemness in colorectal cancer by modulating YY1/CTNNB1 publication-title: Cell Death Dis. doi: 10.1038/s41419-020-2707-6 – volume: 52 start-page: 1544 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0650 article-title: The miRNA–target interactions: an underestimated intricacy publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkad1142 – volume: 5 start-page: 10886 year: 2014 ident: 10.1016/j.bcp.2025.116889_b0475 article-title: The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway publication-title: Oncotarget doi: 10.18632/oncotarget.2540 – volume: 31 start-page: 1349 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0030 article-title: Specificity profiling of deubiquitylases against endogenously generated ubiquitin-protein conjugates publication-title: Cell Chem. Biol. doi: 10.1016/j.chembiol.2024.05.001 – volume: 24 start-page: 7698 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0395 article-title: LncRNA DBH-AS1 facilitates the tumorigenesis of melanoma by targeting miR-223-3p via IGF-1R/AKT signaling publication-title: Eur. Rev. Med. Pharmacol. Sci. – volume: 6 start-page: 6156 year: 2015 ident: 10.1016/j.bcp.2025.116889_b0305 article-title: Tumour suppressor TRIM33 targets nuclear β-catenin degradation publication-title: Nat. Commun. doi: 10.1038/ncomms7156 – volume: 21 start-page: 40 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0445 article-title: MicroRNA-4429 suppresses proliferation of prostate cancer cells by targeting distal-less homeobox 1 and inactivating the Wnt/β-catenin pathway publication-title: BMC Urol. doi: 10.1186/s12894-021-00810-x – volume: 154 start-page: 169 year: 2013 ident: 10.1016/j.bcp.2025.116889_b0180 article-title: OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis publication-title: Cell doi: 10.1016/j.cell.2013.05.046 – volume: 27 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0480 article-title: Integrative modeling and analysis of signaling crosstalk reveal molecular switches coordinating Yes-associated protein transcriptional activities publication-title: IScience doi: 10.1016/j.isci.2024.109031 – volume: 112 start-page: 14 year: 2018 ident: 10.1016/j.bcp.2025.116889_b0070 article-title: YOD1 attenuates neurogenic proteotoxicity through its deubiquitinating activity publication-title: Neurobiol. Dis. doi: 10.1016/j.nbd.2018.01.006 – volume: 12 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0310 article-title: The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions publication-title: Front. Oncol. doi: 10.3389/fonc.2022.1062524 – volume: 13 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0470 article-title: Extracellular vesicles miR-31-5p promotes pancreatic cancer chemoresistance via regulating LATS2-Hippo pathway and promoting SPARC secretion from pancreatic stellate cells publication-title: J. Extracell Vesicles doi: 10.1002/jev2.12488 – volume: 23 start-page: 148 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0005 article-title: Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches publication-title: Mol. Cancer doi: 10.1186/s12943-024-02046-3 – volume: 118 start-page: 889 year: 2018 ident: 10.1016/j.bcp.2025.116889_b0010 article-title: Ubiquitin-like protein conjugation: Structures, chemistry, and mechanism publication-title: Chem. Rev. doi: 10.1021/acs.chemrev.6b00737 – ident: 10.1016/j.bcp.2025.116889_b0590 – volume: 248 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0275 article-title: RNF114 facilitates the proliferation, stemness, and metastasis of colorectal cancer publication-title: Pathol. Res. Pract. doi: 10.1016/j.prp.2023.154716 – ident: 10.1016/j.bcp.2025.116889_b0530 doi: 10.4172/2476-2261.1000129 – volume: 187 start-page: 1617 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0540 article-title: Cancer biomarkers: emerging trends and clinical implications for personalized treatment publication-title: Cell doi: 10.1016/j.cell.2024.02.041 – volume: 107 start-page: 824 year: 2018 ident: 10.1016/j.bcp.2025.116889_b0400 article-title: LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2018.08.079 – volume: 66 start-page: 519 year: 2021 ident: 10.1016/j.bcp.2025.116889_b0145 article-title: Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes publication-title: J. Hum. Genet. doi: 10.1038/s10038-020-00865-y – volume: 16 start-page: 3565 year: 2017 ident: 10.1016/j.bcp.2025.116889_b0485 article-title: MicroRNA-302a suppresses cell proliferation, migration and invasion in osteosarcoma by targeting ADAM9 publication-title: Mol. Med. Rep. doi: 10.3892/mmr.2017.6975 – volume: 21 start-page: 5667 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0160 article-title: Mir-93/mir-375: diagnostic potential, aggressiveness correlation and common target genes in prostate cancer publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms21165667 – volume: 20 start-page: 211 year: 2019 ident: 10.1016/j.bcp.2025.116889_b0460 article-title: Hippo–YAP/TAZ signalling in organ regeneration and regenerative medicine publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/s41580-018-0086-y – volume: 7 start-page: 58 year: 2023 ident: 10.1016/j.bcp.2025.116889_b0235 article-title: Targeting CDK1 in cancer: mechanisms and implications publication-title: NPJ Precis. Oncol. doi: 10.1038/s41698-023-00407-7 – volume: 15 start-page: 556 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0040 article-title: Oxidative cell death in cancer: mechanisms and therapeutic opportunities publication-title: Cell Death Dis. doi: 10.1038/s41419-024-06939-5 – volume: 22 start-page: 8 year: 2024 ident: 10.1016/j.bcp.2025.116889_b0495 article-title: Characterization of gastric cancer-stimulated signaling pathways and function of CTGF in cancer-associated fibroblasts publication-title: Cell Commun. Signal. doi: 10.1186/s12964-023-01396-7 – volume: 24 start-page: 8722 year: 2020 ident: 10.1016/j.bcp.2025.116889_b0140 article-title: MiR-4429 suppresses the malignant development of ovarian cancer by targeting YOD1 publication-title: Eur. Rev. Med. Pharmacol. Sci. |
| SSID | ssj0006861 |
| Score | 2.4722192 |
| SecondaryResourceType | review_article |
| Snippet | [Display omitted]
YOD1 deubiquitinase is a 38 kDa protein that belongs to the ovarian tumour protease (OTU) family, and its dysregulation can precipitate... YOD1 deubiquitinase is a 38 kDa protein that belongs to the ovarian tumour protease (OTU) family, and its dysregulation can precipitate cancer development.... YOD1 deubiquitinase is a 38 kDa protein that belongs to the ovarian tumour protease (OTU) family, and its dysregulation can precipitate cancer development.... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 116889 |
| SubjectTerms | Animals Biomarker Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Deubiquitinase Gene Expression Regulation, Neoplastic - physiology Humans Neoplasms - genetics Neoplasms - metabolism Therapeutic target Translational Research, Biomedical - methods Tumour-regulation YOD1 |
| Title | Decoding YOD1: Insights into tumour regulation and translational opportunities |
| URI | https://dx.doi.org/10.1016/j.bcp.2025.116889 https://www.ncbi.nlm.nih.gov/pubmed/40132762 https://www.proquest.com/docview/3181366588 |
| Volume | 236 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB6KHvQiWl_1UVaQHqSx2Tw2qbfSWlrF6sFCPS27eUBF02LTgxd_uzN5WAT14DEhYZeZ2XnszHwDcN4Wym97PDC4Up7haMKAtN3Q8OxIxwJFxMyKaO5GYjB2bibupALdsheGyioL3Z_r9ExbF29aBTVb8-mUenxNYbXRf3DJ8GdtVo7jkZRffqzKPIQviql5wqCvy8xmVuOlA4KstFxUHMKnSe8_26bffM_MBvW3YatwHlkn398OVKKkChvdcmZbFRoPORL1e5M9rhqrFk3WYA8rjOr3XRj1MOwks8We7nv8ig2TBUXpCzZN0hlLl6-4FHvL59Qj55hKQpaSWXspLg_ZbE6e-zLJEFn3YNy_fuwOjGK0ghHgoU4p3246XuiFYdzWQutA-OjXhBGeT0IMc7RrhgTFFWu6x3EtLXzFTcVjDK_ikGt7H9aSWRIdAtORG8fcVZ6KLCe2hR8EQnmWwiUsZSleg4uSqHKeI2jIsrTsWSIHJHFA5hyogVOSXX4TA4ka_q_fzkoWSaQ45TxUEs2WC4kqi9sC3Sy_Bgc57752QaGlhcbg6H-LHsMmPeV1Yyewlr4to1P0UFJdz0SwDuud4e1g9AnStuOH |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VcigXBC2PtFAWCXpAdeNd22sHiUPVUCV9hB5SqZy2u_YaBbVOVDuqcumf4g8yY6-JkIADUq-27F3NjOab2Z35BuBdT-qkF_PU41rHXmiIAzKIMi8OrMklmohfF9GcjuTgPDy6iC5W4EfbC0Nllc73Nz699tbuSddJszubTKjH15eih_FDRMDPfVdZeWwXt5i3lZ-GfVTyeyEOP48PBp4bLeClaNQV3Tf7YZzFWZb3jDQmlQniembRPokxKzSRnxEVVW7oHCMSRiaa-5rnmF7kGTcB_vcBPAzRXdDYhL27ZV2JTKQb0yc92l57lVoXlZmUODJFhJ5KJjRa_s9g-Ldgtwa9wyfw2EWrbL8RyFNYscU6rB20Q-LWYeesob5e7LLxspOr3GU77GxJir3YgFEf81zCSfb1S59_ZMOipGOBkk2Kasqq-TUuxW7sNzdNjOkiYxXh6JU7rWTTGaUK86KmgH0G5_ci8OewWkwL-xKYsVGe80jH2oowD2SSplLHQuMSQgvNO_ChFaqaNZQdqq1l-65QA4o0oBoNdCBsxa5-szuFkPKvz962KlIocbpk0YWdzkuFPpIHEuO6pAMvGt392gXlsgLRZ_P_Fn0Da4Px6Yk6GY6Ot-ARvWmK1l7BanUzt68xPKrMdm2ODC7v2_5_AmpDHao |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decoding+YOD1%3A+Insights+into+tumour+regulation+and+translational+opportunities&rft.jtitle=Biochemical+pharmacology&rft.au=Zhi-Xiong%2C+Chong&rft.date=2025-06-01&rft.eissn=1873-2968&rft.volume=236&rft.spage=116889&rft_id=info:doi/10.1016%2Fj.bcp.2025.116889&rft_id=info%3Apmid%2F40132762&rft.externalDocID=40132762 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-2952&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-2952&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-2952&client=summon |